세계의 네뷸라이저 시장 규모는 2024년에 13억 7,460만 달러에 달하며, 2032년까지 24억 1,236만 달러에 달할 것으로 예측되며, 2025-2032년의 예측 기간에 CAGR로 7.32%의 성장이 전망됩니다. 천식, 만성폐쇄성폐질환(COPD) 등 만성 호흡기 질환의 부담 증가와 흡연의 급증으로 인해 폐에 직접 약물을 투여하는 데 필수적인 분무기를 포함한 효과적인 치료 옵션에 대한 수요가 증가함에 따라 시장이 크게 성장하고 있습니다. 동시에 재택치료기기 증가로 재택 치료를 선호하는 환자나 재택 치료를 필요로 하는 환자들에게 분무기가 더 친숙하고 편리해져 시장 확대가 촉진되고 있습니다. 또한 호흡기 질환의 조기 진단과 관리를 강화하는 인식 제고와 종합적인 스크리닝 프로그램도 호흡기 질환의 조기 진단과 관리를 강화하는 데 중요한 역할을 하고 있으며, 분무기 치료에 대한 수요를 증가시키고 있습니다. 또한 시장 선도 기업의 제품 출시와 규제 당국의 승인 증가로 인해 다양한 환자의 요구와 선호도를 충족시킬 수 있는 휴대가 가능하고 보다 효율적인 기기 등 진보적이고 혁신적인 분무기 기술이 도입되고 있습니다. 이러한 요인들은 2025-2032년의 예측 기간 중 증가하는 환자 인구의 니즈, 기술 발전, 호흡기 질환에 대한 접근성 및 관리 개선 등을 통해 시장의 건전한 성장에 기여할 것으로 예측됩니다.
분무기 시장 역학
Australian Institute of Health and Welfare가 제공한 최신 데이터에 따르면 2022년 호주에서 약 850만 명(34%)이 만성 호흡기 질환을 앓고 있는 것으로 추정됩니다.
또한 Global Burden of Disease(2023)가 제공한 최신 데이터에 따르면 전 세계 인구 약 20명 중 1명이 만성 호흡기 질환을 앓고 있습니다.
또한 세계보건기구(WHO)(2023)의 최근 데이터에 따르면 흡연은 만성폐쇄성폐질환의 주요 원인이며, 호흡곤란을 유발하는 흔한 폐질환으로 연간 300만 명 이상의 생명을 앗아가는 것으로 나타났습니다. 약 3억 9,200만 명이 COPD를 앓고 있으며, 그 중 약 75%가 중저소득 국가에 거주하고 있습니다. 고소득 국가에서는 흡연이 COPD 환자의 70% 이상을 차지합니다.
흡연과 환경적 요인으로 인해 호흡기 질환의 발병률이 증가함에 따라 분무기에 대한 니즈가 증가하고 있습니다. 분무기는 효과적인 증상 완화 및 질병 관리를 위해 폐에 직접 약물을 투여하는 데 중요한 역할을 합니다.
또한 GLOBOCAN이 제공한 최근 데이터에 따르면 2022년 전 세계에서 새로 발생한 것으로 추정되는 기관지, 기관지, 폐암 환자는 248만 명이며, 2045년까지 425만 명으로 증가할 것으로 예측됩니다. 폐암 환자의 경우, 분무기는 호흡곤란, 기침, 점액 분비 등의 부작용을 관리하는 데 도움이 되는 약물을 투여하는 데 사용할 수 있습니다. 폐암 발병률이 증가함에 따라 분무기를 포함한 지지요법 툴의 필요성이 증가하고 있습니다. 또한 폐암 환자들은 호흡기 합병증을 유발할 수 있는 치료를 받는 경우가 많아 증상을 완화하고 삶의 질을 개선하는 분무기 치료에 대한 수요가 더욱 증가하고 있습니다.
또한 기업은 분무기 생산을 확대하고 규제 당국의 승인을 확보함으로써 시장 입지를 전략적으로 확장하고 추가 성장을 가속하고 있습니다. 예를 들어 2024년 5월 Medline은 Hudson RCI TurboMist 소량 분무기를 자사의 호흡기 관리 포트폴리오에 추가한다고 발표했습니다. TurboMist는 단 3분 만에 치료제를 투여할 수 있으며, 시중에서 판매되는 소량 분무기 중 가장 빠르게 치료제를 투여할 수 있도록 설계되었습니다.
따라서위의 요인은 예측 기간 중 분무기 시장을 밀어 붙일 가능성이 높습니다.
그러나 대체 약물전달의 가용성 및 복용량 중 약물 손실이 분무기의 미래 시장을 저해할 수 있습니다.
세계의 네뷸라이저 시장에 대해 조사분석했으며, 시장 규모와 예측, 과거 3년 제품/기술개발, 시장의 주요 기업, 이용 가능한 기회 등의 정보를 제공하고 있습니다.
Nebulizers Market by Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer), Portability (Tabletop Nebulizer and Portable Nebulizer), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Emergency Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising burden of chronic respiratory diseases, the surge in cigarette smoking, increase in home healthcare devices, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.
The nebulizers market was valued at USD 1,374.60 million in 2024, growing at a CAGR of 7.32% during the forecast period from 2025 to 2032, to reach USD 2,412.36 million by 2032. The nebulizer market is experiencing significant growth due to the rising burden of chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and the surge in smoking which has led to an increased demand for effective treatment options, including nebulizers, which are essential for delivering medication directly to the lungs. Simultaneously, the increase in home healthcare devices has made nebulizers more accessible and convenient for patients who prefer or require home-based treatment, driving market expansion. Additionally, growing awareness and comprehensive screening programs have also played a crucial role by enhancing early diagnosis and management of respiratory conditions, thereby increasing the need for nebulization therapy. Furthermore, the surge in product launches and regulatory approvals by leading market players introduces advanced and innovative nebulizer technologies, such as portable and more efficient devices, which cater to diverse patient needs and preferences. Collectively, these factors contribute to robust market growth by addressing the needs of a growing patient population, advancing technology, and improving accessibility and management of respiratory diseases during the forecast period from 2025 to 2032.
Nebulizers Market Dynamics:
According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions.
Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately, 1 in 20 people globally suffered from chronic respiratory diseases.
Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people have COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases.
As the incidence of respiratory disorders rises, driven largely by smoking and environmental factors, there is a heightened need for nebulizers, which are critical in delivering medication directly to the lungs for effective symptom relief and disease management.
Additionally, as per the recent data provided by GLOBOCAN, in 2022, globally the estimated new cases of trachea, bronchus, and lung cancer was 2.48 million, and the projections are expected to rise by 4.25 million by the year 2045. For patients with lung cancer, nebulizers can be used to deliver medications that help manage side effects such as shortness of breath, cough, and mucus production. As the incidence of lung cancer rises, the need for supportive care tools, including nebulizers, increases. Additionally, lung cancer patients often undergo treatments that can lead to respiratory complications, further driving the demand for nebulization therapy to alleviate symptoms and improve quality of life.
Additionally, companies are amplifying their production of nebulizers and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in May 2024, Medline announced the addition of the Hudson RCI TurboMist small volume nebulizer to its respiratory care portfolio. The TurboMist delivered medication treatments in as little as three minutes and was designed to be the fastest small volume nebulizer available.
Thus, the factors mentioned above are likely to boost the market of nebulizers during the forecasted period.
However, the availability of alternative drug delivery and drug loss during medication dosage to be consumed may hinder the future market of nebulizers.
Nebulizers Market Segment Analysis:
Nebulizers by Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer), Portability (Tabletop Nebulizer and Portable Nebulizer), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Emergency Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the type segment of the nebulizers market the jet nebulizers are expected to hold a significant share in 2024. The large market share of this product segment can be attributed to the growing patient adoption of these devices, quick treatment, mobility, and simplicity. Moreover, jet nebulizers are capable of delivering the drug in the form of droplets in the size range of 1-5 mm, with the help of baffles incorporated due to their design. These nebulizers are mostly used for bronchodilator administration to produce a physiological response. Both technical and patient factors are involved in the growth performance of the jet nebulizers segment. Technical factors, like the gas flow, the volume of the nebulizer solution, and the nebulizer output, play a crucial role in better drug delivery. Also, the low cost of jet nebulizers is significantly boosting the nebulizers market growth. This, in turn, is expected that the jet nebulizer segment will grow over the forecast period, which will also help in driving the overall global nebulizers market growth.
Furthermore, due to precise medication administration to the lungs and lower residual quantities, jet nebulizers are gaining commercial acceptability, which improves market penetration. All these advantages of these devices make physicians more inclined to use jet nebulizers.
In addition, new product approvals are also likely to upsurge the Global Nebulizers market during the forecasted period. For instance, in January 2021, Wellinks announced the initiation of IRB approved study of digital health solutions for COPD, it will utilize a Bluetooth(TM) enabled version of Wellinks' Flyp Nebulizer and a suite of connected diagnostic tools including spirometry and pulse-oximetry.
Additionally, a shift in trend from table-top to portable devices will offer assistance in remote settings. This will increase the acceptance of nebulizers for patients. Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global nebulizers market during the forecast period.
North America is expected to dominate the overall nebulizers market:
North America is expected to account for the highest proportion of the nebulizers market in 2024, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, increase in technological advancement, increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of nebulizers during the forecast period.
According to the recent data and stats provided by the American Lung Association (2024), in 2022, among children, asthma was more common in males accounting for 7.0% of the population in the United States and 5.4% in females. Additionally, as per the same source, asthma among adults is 10.8% for females and 6.5% for females across the region of the United States. Asthma, a chronic respiratory condition characterized by airway inflammation and constriction, requires consistent management to control symptoms and prevent exacerbations. Nebulizers are vital in delivering medications, such as bronchodilators and corticosteroids, directly to the lungs, providing quick and effective relief from asthma symptoms. As the prevalence of asthma rises globally, driven by factors like environmental pollution and increased awareness of the condition, there is a corresponding increase in the need for nebulizers thereby boosting the overall market across the region.
Additionally, as per the data provided by the Centre for Disease Control and Prevention (2024), in 2022, 4.6% of adults had been diagnosed with COPD, emphysema, or chronic bronchitis in the United States. As nebulizers are essential for delivering medication to help alleviate symptoms and manage these diseases, the prevalence of such conditions directly drives demand for these devices. With a notable portion of the adult population needing ongoing respiratory care, healthcare providers and patients are likely to seek out nebulizers to improve quality of life and manage symptoms more effectively thereby boosting the market.
Furthermore, as per the recent data and stats provided by the Centre for Disease Control and Prevention (2023), approximately 11.5% of U.S. adults aged 18 and older smoked cigarettes, totaling around 28.3 million smokers. At that time, over 16 million Americans were living with a smoking-related disease. The high prevalence of smoking-related diseases drives the need for nebulizers, as they are essential in delivering medication to alleviate symptoms and improve respiratory function. This significant patient population creates a strong demand for nebulizers, boosting the market.
Further, in North America and at the global level the United States represents the largest market worldwide supported by developed healthcare infrastructure and strong adoption of technologically advanced products owing to the rise in healthcare expenditure by the government and increased prevalence and incidence of respiratory disease as mentioned above. One such technological advancement is the AeroEclipse BAN nebulizer, it is the world's only breath-actuated small volume nebulizer, developed by Trudell Medical International in Canada.
The increasing number of product development activities in the region is further going to accelerate the growth of the nebulizers market. In August 2021, Smiths Medical announced the launch of the acapella(R) choice blue vibratory PEP therapy system. Vibratory PEP therapy is a drug-free supplemental treatment that can reduce COPD flare-ups and hospital length of stay by 1.5 days. The acapella(R) Choice blue system is designed to effectively deliver medication when combined with a nebulizer.
Therefore, the above-mentioned factors are expected to bolster the growth of the nebulizers market in North America during the forecast period.
Nebulizers Market Key Players:
Some of the key market players operating in the Nebulizers market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., Allied Healthcare Products Inc., TEKCELEO, BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Convexity Scientific Inc., Rossmax International Ltd., and others.
Recent Developmental Activities in the Nebulizers Market:
Key takeaways from the nebulizers market report study:
Target audience who can benefit from this nebulizers market report study:
Frequently Asked Questions for the Nebulizers Market: